• Pigmentation disorders

Avage Generic Name & Formulations

General Description

Tazarotene 0.1%; crm.

Pharmacological Class


How Supplied



Avage Indications


Adjunct to comprehensive skin care and sunlight avoidance programs in the palliation of facial fine wrinkles, facial mottled hyper- and hypopigmentation, and facial benign lentigines.

Limitations of Use

Does not eliminate or prevent wrinkles or restore more youthful skin. Does not reverse photoaging or repair sun damaged skin; does not mitigate coarse or deep wrinkling, tactile roughness, telangiectasia, skin laxity, keratinocytic atypia, melanocytic atypia, or dermal elastosis. The safety and effectiveness for the prevention or treatment of actinic keratoses, skin neoplasms, or lentigo maligna have not been established.

Avage Dosage and Administration


≥17yrs: apply thin film to entire face once daily in the PM. Females of reproductive potential: begin therapy during normal menses.


<17yrs: not established.

Avage Contraindications



Avage Boxed Warnings

Not Applicable

Avage Warnings/Precautions


Assess any facial pigmented lesions (eg, lentigo maligna) prior to initiation. Obtain reliable negative pregnancy test within 2 weeks prior to therapy. Females of reproductive potential should use effective contraception. Do not use on broken, eczematous, or sunburned skin. Sun sensitivity. Avoid eyes, mouth, sun, and UV light. Increased irritation in extreme weather. Discontinue or reduce dose frequency if excessive irritation occurs. Nursing mothers.

Avage Pharmacokinetics

See Literature

Avage Interactions


Avoid use until the effects of strong drying agents have subsided. Avoid concomitant with photosensitizers or other irritants.

Avage Adverse Reactions

Adverse Reactions

Desquamation, erythema, burning, dry or irritation skin, pruritus, irritant contact dermatitis, stinging, rash, cheilitis.

Avage Clinical Trials

See Literature

Avage Note

Not Applicable

Avage Patient Counseling

See Literature